| Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor M Behdani, S Zeinali, H Khanahmad, M Karimipour, N Asadzadeh, ... Molecular immunology 50 (1-2), 35-41, 2012 | 141 | 2012 |
| Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth M Behdani, S Zeinali, M Karimipour, H Khanahmad, S Schoonooghe, ... New biotechnology 30 (2), 205-209, 2013 | 118 | 2013 |
| Single-domain antibodies or nanobodies: a class of next-generation antibodies F Khodabakhsh, M Behdani, A Rami, F Kazemi-Lomedasht International reviews of immunology 37 (6), 316-322, 2018 | 110 | 2018 |
| Albumin nanoparticles as nanocarriers for drug delivery: Focusing on antibody and nanobody delivery and albumin-based drugs E Karami, M Behdani, F Kazemi-Lomedasht Journal of Drug Delivery Science and Technology 55, 101471, 2020 | 86 | 2020 |
| Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody F Kazemi-Lomedasht, M Behdani, KP Bagheri, M Habibi-Anbouhi, ... Molecular immunology 65 (1), 58-67, 2015 | 85 | 2015 |
| Oral DNA vaccines based on CS-TPP nanoparticles and alginate microparticles confer high protection against infectious pancreatic necrosis virus (IPNV) infection in trout S Ahmadivand, M Soltani, M Behdani, Ø Evensen, E Alirahimi, ... Developmental & Comparative Immunology 74, 178-189, 2017 | 74 | 2017 |
| T cell engineered with a novel nanobody‐based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy F Hajari Taheri, M Hassani, Z Sharifzadeh, M Behdani, A Arashkia, ... IUBMB life 71 (9), 1259-1267, 2019 | 67 | 2019 |
| An overview on application of phage display technique in immunological studies A Rami, M Behdani, N Yardehnavi, M Habibi-Anbouhi, ... Asian Pacific Journal of Tropical Biomedicine 7 (7), 599-602, 2017 | 67 | 2017 |
| The first report on transcriptome analysis of the venom gland of Iranian scorpion, Hemiscorpius lepturus F Kazemi-Lomedasht, V Khalaj, KP Bagheri, M Behdani, ... Toxicon 125, 123-130, 2017 | 52 | 2017 |
| Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3) V Homayouni, M Ganjalikhani-Hakemi, A Rezaei, H Khanahmad, ... Iranian Journal of Basic Medical Sciences 19 (11), 1201, 2016 | 47 | 2016 |
| Rapid and low-cost colorimetric method using 2,3,5-triphenyltetrazolium chloride for detection of multidrug-resistant Mycobacterium tuberculosis A Mohammadzadeh, P Farnia, K Ghazvini, M Behdani, T Rashed, ... Journal of medical microbiology 55 (12), 1657-1659, 2006 | 47 | 2006 |
| Anti-HER2 scFv Expression in Escherichia coli SHuffle®T7 Express Cells: Effects on Solubility and Biological Activity M Ahmadzadeh, F Farshdari, L Nematollahi, M Behdani, E Mohit Molecular biotechnology 62 (1), 18-30, 2020 | 46 | 2020 |
| VP2 (PTA motif) encoding DNA vaccine confers protection against lethal challenge with infectious pancreatic necrosis virus (IPNV) in trout S Ahmadivand, M Soltani, M Behdani, Ø Evensen, E Alirahimi, E Soltani, ... Molecular immunology 94, 61-67, 2018 | 46 | 2018 |
| Design and characterization of short hybrid antimicrobial peptides from pEM‐2, mastoparan‐VT 1, and mastoparan‐B H Memariani, D Shahbazzadeh, R Ranjbar, M Behdani, M Memariani, ... Chemical Biology & Drug Design 89 (3), 327-338, 2017 | 45 | 2017 |
| Nanobodies as novel therapeutic agents in envenomation E Alirahimi, F Kazemi-Lomedasht, D Shahbazzadeh, M Habibi-Anbouhi, ... Biochimica et Biophysica Acta (BBA)-General Subjects 1862 (12), 2955-2965, 2018 | 41 | 2018 |
| Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function F Kazemi-Lomedasht, S Muyldermans, M Habibi-Anbouhi, M Behdani Iranian journal of basic medical sciences 21 (3), 260, 2018 | 38 | 2018 |
| A camelid antibody candidate for development of a therapeutic agent against Hemiscorpius lepturus envenomation N Yardehnavi, M Behdani, KP Bagheri, A Mahmoodzadeh, H Khanahmad, ... The FASEB Journal 28 (9), 4004, 2014 | 38 | 2014 |
| Development of a mono‐specific anti‐VEGF bivalent nanobody with extended plasma half‐life for treatment of pathologic neovascularization A Sadeghi, M Behdani, S Muyldermans, M Habibi‐Anbouhi, ... Drug testing and analysis 12 (1), 92-100, 2020 | 35 | 2020 |
| A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis E Karami, JM Sabatier, M Behdani, S Irani, F Kazemi-Lomedasht Journal of enzyme inhibition and medicinal chemistry 35 (1), 1233-1239, 2020 | 33 | 2020 |
| Construction and expression of an anti-VEGFR2 Nanobody-Fc fusionbody in NS0 host cell M Qasemi, M Behdani, MA Shokrgozar, V Molla-Kazemiha, ... Protein Expression and Purification 123, 19-25, 2016 | 31 | 2016 |
Fatemeh Kazemi-LomedashtAssociate Professor, Medical Biotechnology, Pasteur Institute of Iranایمیل تأیید شده در pasteur.ac.ir